17 July 2020 : Original article
Kidney Transplantation and “Sex Mismatch”: A 10-Year Single-Center Analysis
Karol Graňák1ABCDE, Lea Kováčiková1ABC, Petra Skálová1AB, Matej Vnučák1BDE, Juraj Miklušica1ABCD, Ľudovít Laca1ABC, Marián Mokáň2FG, Ivana Dedinská1ACEF*DOI: 10.12659/AOT.921117
Ann Transplant 2020; 25:e921117
Table 1 Group characteristics.
| Whole group of patients | Donor n=230 | Recipient n=230 | P-value |
|---|---|---|---|
| Age at the time of procurement/KT (years) | 45±15.3 | 47.4±11.6 | 0.0586 |
| Gender – men (%) | 70.4 | 67 | 0.4322 |
| BMI (kg/m) | 24.7±3.9 | – | – |
| ECD donor (%) | 29.1 | – | – |
| eGFR at the time of procurement (ml/min) | 82.5±32.1 | – | – |
| QVPU before procurement (g/sampling) | 0.9±0.6 | – | – |
| CIT (min) | – | 650±304 | – |
| DGF (%)* | – | 10.9 | – |
| Induction: basiliximab/daclizumab (%) | – | 57.4 | – |
| Induction: thymoglobulin (%) | – | 27.8 | – |
| Induction: None (%) | – | 14.8 | |
| Tacrolimus (%) | – | 81.7 | – |
| Cyclosporine A (%) | – | 18.3 | – |
| Creatinine D7 (μmol/l) | – | 230±194 | – |
| Creatinine M1 (μmol/l) | – | 159±70 | – |
| Creatinine M3 (μmol/l) | – | 157±48 | – |
| Creatinine M6 (μmol/l) | – | 144±51 | – |
| Creatinine Y1 (μmol/l) | – | 142±53 | – |
| Creatinine Y3 (μmol/l) | – | 136±50 | – |
| Creatinine Y5 (μmol/l) | – | 131±36 | – |
| eGFR M1 (ml/min) | – | 42.3±12.7 | – |
| eGFR M3 (ml/min) | – | 41.9±12.6 | – |
| eGFR M6 (ml/min) | – | 44.3±14 | – |
| eGFR R1 (ml/min) | – | 47.3±14.8 | – |
| eGFR R3 (ml/min) | – | 50±13.3 | – |
| eGFR R5 (ml/min) | – | 48.2±12.4 | – |
| Acute rejection in anamnesis (%)** | – | 23.9 | – |
| KT – kidney transplantation; BMI – body mass index; ECD – expanded criteria donors; eGFR – estimated glomerular filtration rate (according to CKD/EPI formula); QVPU – quantitative proteinuria; CIT – cold ischemia time; DGF – delayed graft function; D – day; M – month; Y – year. * Needed dialysis treatment in the first week after kidney transplantation; ** follow up: 1 year. | |||